fb88

Oct 21, 2022

On October 19, 2022, the Food and Drug Administration (FDA) reissued an Emergency Use Authorization letter (EUA) for the use of Monovalent COVID-19 vaccine booster doses from . The American Medical Association (AMA) updated their to include the Current Procedural Terminology (CPT) codes as shown in the table below.   

The Office of fb88Care Services (OMS) will be updating our system to include this code. We are asking providers to hold all claims for the Novavax Monovalent COVID-19 vaccine booster dose and its administration for all members ages 18 years and older until this system update is complete. 

 

Novavax COVID-19 Vaccine Monovalent Booster Dose
Code	Description	Effective Date	fb88Care Rate
91304+	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use	07/13/22	$0*
0044A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponinbased adjuvant, preservative free, 5 mcg/0.5 mL dosage; booster dose	10/19/22	TBD**
*Government Supplied Vaccines  **Rates for these codes are not yet established  +Code previously released 07/13/22 as part of the Novavax COVID-19 vaccine primary series  Note: The COVID-19 vaccine administration codes will be added for

 

Providers may visit the fb88 CDC Immunization Program Website for up-to-date information on administering and ordering COVID-19 vaccine and booster doses. The fb88 CDC also issued this that includes information on COVID-19 vaccine booster doses. 

If you have questions about the use of Monovalent or Bivalent COVID-19 vaccine booster doses, please contact your Provider Relations Specialist. &²Ô²ú²õ±è;